Framework Charts a 3-Stage Path to Catch Psoriatic Arthritis Early

For many patients with psoriasis, the disease that starts on the skin does not always stay there. Psoriatic arthritis develops in roughly 20% to 30% of people with psoriasis, and more than 80% of those cases follow a clinically silent stretch of immune activation that current care rarely screens for before joint damage begins, according to a structured literature review published in Clinical and Experimental Rheumatology.¹

Screening Gaps Leave an Early Window Unclaimed

Dermatology clinics do not routinely test for psoriatic arthritis (PsA), even though the condition affects roughly 1 in 3 people with psoriasis and can cause permanent damage to bones and joints if it goes untreated.² The National Psoriasis Foundation recommends that people with psoriasis complete a validated 5-question screening tool, the Psoriasis Epidemiology Screening Tool (PEST), every 6 months; in data the foundation cites, 41% of patients who screened positive using PEST had not previously been diagnosed with PsA, a sign of how much disease can go unrecognized between visits.

The review's authors framed PsA not as a single clinical event but as a staged continuum.¹ An at-risk phase involves systemic immune activation without musculoskeletal symptoms; a subclinical phase brings arthralgia or imaging-detected inflammation without overt arthritis; and clinical PsA arrives once synovitis, enthesitis, or dactylitis meets formal classification criteria. Long-term predictors of eventual transition include psoriasis severity, nail disease, family history, and obesity, while arthralgia and imaging-detected enthesitis or synovitis signal that transition may be imminent.

Mapping Two Decades of Psoriatic Arthritis Research

The authors searched PubMed/MEDLINE from January 2000 through June 2025 for English-language, peer-reviewed studies on the psoriasis-to-PsA transition, covering immunogenetics, staging frameworks, screening tools, imaging, and interception strategies. Two reviewers independently screened titles and abstracts and resolved disagreements by consensus, narrowing the field to 82 articles for synthesis after full-text review, supplemented by manual reference-list searches.

Case reports and pediatric studies were excluded, and non-English publications were included only when an English abstract was available. That scope kept the evidence base to peer-reviewed, human clinical, imaging, and biomarker research in adults with psoriasis or a family history of the disease.

Imaging and Genetic Markers Flag Risk Before Symptoms Appear

Ultrasonography and magnetic resonance imaging (MRI) can reveal subclinical synovitis and enthesitis in patients with psoriasis who have no joint symptoms at all, and emerging PET imaging using a fibroblast-activation tracer detected abnormal signal at synovial and entheseal sites even before ultrasonographic changes appeared. Genetic markers add another layer: human leukocyte antigen (HLA)-B27 tracks with axial and entheseal disease, HLA-B38 and HLA-C*06 with peripheral joint involvement, and genome-wide studies implicated genes tied to the interleukin (IL)-23/IL-17 pathway that also drives psoriasis itself.

Five validated screening questionnaires, including PEST, ToPAS-2, and EARP, help dermatologists flag patients for rheumatology referral, with EARP reported as the most accurate overall and ToPAS-2 best suited to early, multisite disease. Dactylitis, though uncommon in subclinical disease, appeared in about 10% of patients and usually signaled the transition to overt PsA.

“PsA rarely presents de novo; it usually evolves after a 3- to 10-year subclinical interval following cutaneous [psoriasis],” the researchers wrote. “Exploiting this window demands dermatology-led risk stratification combined with targeted musculoskeletal imaging for early rheumatology referral.”

Early Biologic Treatment Tracks With Lower Arthritis Risk

Observational data suggest that treating psoriasis itself, rather than waiting for joint symptoms, may blunt the transition to PsA. One cohort linked continuous biologic therapy for psoriasis to a markedly lower risk of incident PsA compared with ultraviolet B phototherapy (hazard ratio [HR], 0.27), and a monocentric cohort found PsA prevalence of 8.9% among patients on biologics, including tumor necrosis factor, IL-17, and IL-23 inhibitors, vs 26.1% among those not on biologic therapy. A decade-long, propensity-matched analysis found sustained protection specifically with tumor necrosis factor blockade (HR, 0.32).

In a referral cohort of 203 patients with psoriasis, systemic therapy, particularly biologics, was linked to a 3- to 4-fold reduction in incident PsA compared with topical treatment or no treatment, though a residual PsA prevalence of about 40% in that group points to partial, not complete, interception. Separately, tight, treat-to-target management begun within the first year of clinical PsA significantly outperformed usual care on joint and skin outcomes alike.

Psoriatic Arthritis Prevention Trials Remain the Missing Piece

The authors cautioned that definitive prevention trials remain pending. Most of the evidence linking early or biologic therapy to lower PsA risk comes from observational and registry cohorts rather than randomized trials built specifically to test interception, leaving room for residual confounding, and no validated biomarker or imaging threshold yet reliably predicts which patients with subclinical inflammation will progress to clinical arthritis.

For dermatologists, rheumatologists, and the patients they share, the takeaway is practical: those with high-risk psoriasis phenotypes, such as nail or scalp disease or a family history of PsA, are reasonable candidates for periodic screening and closer dermatology-rheumatology coordination, even before joint symptoms emerge. Prospective, biomarker-driven trials and integrated referral pathways, the authors wrote, will ultimately determine whether that earlier window can be turned into fewer irreversible joint outcomes.

References

1. Caso F, Cascone M, Girolimetto N, et al. Intercepting the psoriasis-psoriatic arthritis continuum: a precision-medicine framework for at-risk, subclinical, and early psoriatic arthritis. Clin Exp Rheumatol. 2026;44:1429-1442.
2. National Psoriasis Foundation. Psoriatic arthritis screening test. Accessed August 24, 2026. https://www.psoriasis.org/psoriatic-arthritis-screening-test/